HomeAI · summaries
Storia in 4 fonti
World-first trial to test whether Alzheimer’s drug can delay or prevent disease
Jump to contentAllNewsSportCultureLifestyleSurrey and Borders Partnership NHS Foundation Trust has become the first site in Europe to join an international trial for a prospective Alzheimer's drug. The trial will recruit 1,600 healthy adults aged between 55 and 80 to test whether the drug Trontinemab can delay or prevent the onset of Alzheimer's disease. UK participants will be screened for memory loss and given a blood test to check for the p-tau217 biomarker before receiving the treatment. Developed by Roche, Trontinemab is delivered intravenously and targets harmful amyloid plaques that damage brain cell function. Chief investigator Professor Ramin Nilforooshan highlighted that the study shifts research focus towards intervening before symptoms appear. In fullAlzheimer’s drug to be offered to people without symptoms in bid to prevent onset of diseaseMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
dailymail.com
Healthy Britons to get Alzheimer's drug in trial to prevent dementia
The first participants in Europe will be screened in Britain from Monday, with more than 15 UK centres expected to take part in the global study.
- ·
theguardian.com
Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented
Healthy middle-aged people deemed to be at higher risk of developing condition among those eligible to participate
